Propranolol for Infantile Hemangiomas: Early Experience at a Tertiary Vascular Anomalies Center

被引:131
作者
Buckmiller, Lisa M. [1 ]
Munson, Patrick D. [1 ]
Dyamenahalli, Umesh [2 ]
Dai, Yuemeng [1 ]
Richter, Gresham T. [1 ]
机构
[1] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Otolaryngol, Div Pediat Otolaryngol, Little Rock, AR 72202 USA
[2] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Pediat, Little Rock, AR 72202 USA
关键词
Propranolol; hemangioma; birthmark; beta-blocker; CLASSIFICATION; VINCRISTINE; CHILDREN; INFANCY;
D O I
10.1002/lary.20807
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives/Hypothesis: Propranolol has recently been introduced as a novel pharmacologic treatment for infantile hemangiomas Systematic examination of this treatment in a tertiary care setting has not been described This study explores the impact of propranolol on both proliferative and involuting hemangiomas at a tertiary vascular anomalies center. Study Design: Retrospective single institution review Materials and Methods: We reviewed children treated with propranolol for problematic hemangiomas followed by a blinded prospective analysis of serial photographs taken during the course of their therapy Parental questionnaires were obtained to evaluate perceived therapeutic response and complications to oral propranolol. Results: Thirty-two children with complete photo documentation were treated with oral propranolol for infantile hemangiomas between September 2008 and June 2009 Twenty-seven patients began therapy during the proliferative phase of their lesions (mean age, 4 9 months), whereas five patients began during the involutional phase (mean age, 19.4 months) Ninety-seven percent of patients displayed improvement in the quality of their hemangiomas during propranolol therapy Patients were determined to be excellent responders (n = 16, 50%), partial responders (n = 15, 47%), or nonresponders (n = 1, 3%) Partial and nonresponders received adjuvant therapy (75%, laser therapy; 31%, steroid injections). Ten patients experienced minor but reportable side effects to propranolol, including somnolence (27.2%), gastroesophageal reflux (9.1%), respiratory syncytial virus exacerbation (4.5%), and rash (4.5%). Conclusions: Propranolol may revolutionize the treatment of problematic hemangiomas that cause imminent functional or cosmetic sequelae. At therapeutic doses, propranolol is safe and effective in the majority of patients. Adjunctive therapies may still be required Minor side effects, expected from beta-blocker therapy, are common but easily managed.
引用
收藏
页码:676 / 681
页数:6
相关论文
共 15 条
  • [1] Propranolol for Airway Hemangiomas: Case Report of Novel Treatment
    Buckmiller, Lisa
    Dyamenahalli, Umesh
    Richter, Gresham T.
    [J]. LARYNGOSCOPE, 2009, 119 (10) : 2051 - 2054
  • [2] Growth characteristics of infantile hemangiomas: Implications for management
    Chang, Linda C.
    Haggstrom, Anita N.
    Drolert, Beth A.
    Baselga, Eulalia
    Chamlin, Sarah L.
    Garzon, Maria C.
    Horii, Kimberly A.
    Lucky, Anne W.
    Mancini, Anthony J.
    Metry, Denise W.
    Nopper, Amy J.
    Frieden, Ilona J.
    [J]. PEDIATRICS, 2008, 122 (02) : 360 - 367
  • [3] Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma
    Denoyelle, Francoise
    Leboulanger, Nicolas
    Enjolras, Odile
    Harris, Robert
    Roger, Gilles
    Garabedian, Erea-Noel
    [J]. INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2009, 73 (08) : 1168 - 1172
  • [4] Primary care - Hemangiomas in children
    Drolet, BA
    Esterly, NB
    Frieden, IJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (03) : 173 - 181
  • [5] Vincristine as a treatment for a large haemangioma threatening vital functions
    Fawcett, SL
    Grant, I
    Hall, PN
    Kelsall, AWR
    Nicholson, JC
    [J]. BRITISH JOURNAL OF PLASTIC SURGERY, 2004, 57 (02): : 168 - 171
  • [6] Prospective study of infantile hemangiomas: Demographic, prenatal, and perinatal characteristics
    Haggstrom, Anita N.
    Drolet, Beth A.
    Baselga, Eulalia
    Chamlin, Sarah L.
    Garzon, Maria C.
    Horii, Kimberly A.
    Lucky, Anne W.
    Mancini, Anthony J.
    Metry, Denise W.
    Newell, Brandon
    Nopper, Amy J.
    Frieden, Ilona J.
    [J]. JOURNAL OF PEDIATRICS, 2007, 150 (03) : 291 - 294
  • [7] Prospective study of infantile hemangiomas: Clinical characteristics predicting complications and treatment
    Haggstrom, Anita N.
    Drolet, Beth A.
    Baselga, Eulalia
    Chamlin, Sarah L.
    Garzon, Maria C.
    Horii, Kimberly A.
    Lucky, Anne W.
    Mancini, Anthony J.
    Metry, Denise W.
    Newell, Brandon
    Nopper, Amy J.
    Frieden, Ilona J.
    [J]. PEDIATRICS, 2006, 118 (03) : 882 - 887
  • [8] Propranolol for severe hemangiomas of infancy
    Leaute-Labreze, Christine
    de la Roque, Eric Dumas
    Hubiche, Thomas
    Boralevi, Franck
    Thambo, Jean-Benoit
    Taieb, Alain
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24) : 2649 - 2651
  • [9] MULLIKEN JB, 1982, PLAST RECONSTR SURG, V70, P120
  • [10] HEMANGIOMAS AND VASCULAR MALFORMATIONS IN INFANTS AND CHILDREN - A CLASSIFICATION BASED ON ENDOTHELIAL CHARACTERISTICS
    MULLIKEN, JB
    GLOWACKI, J
    [J]. PLASTIC AND RECONSTRUCTIVE SURGERY, 1982, 69 (03) : 412 - 420